Latest Pharmalot News and Updates : Pharmalot updates, Pharmalot News , Pharmalot around the world

Nishadil

Washington | 19°C (overcast clouds)

The Price of Life: Will South Africa Gain Access to Gilead's Breakthrough HIV Drug?

Top story

The Price of Life: Will South Africa Gain Access to Gilead's Breakthrough HIV Drug?

In focus

Latest feed

Virginia's Bold Move: A New Era for Prescription Drug Affordability

The Shifting Sands of Pharma: FDA's Grip, Global Ambitions, and the Future of Medicine

Unpacking Trump's Vision for 340B: A Pilot Program's Complex Ripples

Pharmalot's Pulse Check: Navigating Pharma's Twists and Turns

Latest headlines

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Shifting Sands of Pharma: Innovation, Access, and Lingering Questions in Early 2026

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

The Pharmaceutical Frontier: Navigating Breakthroughs, Billions, and Bitter Debates

The Evolving Landscape of Pharma and Biotech Employment

The Evolving Landscape of Pharma and Biotech Employment

Navigating the Complex Currents of Modern Pharmaceuticals

Navigating the Complex Currents of Modern Pharmaceuticals

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

The 'Skinny Label' Showdown: How a Supreme Court Case Could Redefine Generics and Drug Prices

Unpacking Pharma's Future: Costs, Generics, and the Tug-of-War for Access

Unpacking Pharma's Future: Costs, Generics, and the Tug-of-War for Access

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

The Pharmaceutical Pulse: A Year-End Reflection on Innovation, Politics, and Public Trust in 2025

Pharma's Unfolding Drama: 340B Clashes, Vaccine Progress, and Cancer Innovation

Pharma's Unfolding Drama: 340B Clashes, Vaccine Progress, and Cancer Innovation

The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

The Fight for Affordable Medicine: Hospitals Take On 340B Program Changes

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

The Great Pharma Race: GLP-1s, Billions, and the Battle for What's Next

A New Hope for Kidney Disease Patients? FDA Greenlights Voyxact, But Pricing Questions Linger

A New Hope for Kidney Disease Patients? FDA Greenlights Voyxact, But Pricing Questions Linger

The Shifting Sands of Pharma and Biotech: Navigating a Dynamic Job Market

The Shifting Sands of Pharma and Biotech: Navigating a Dynamic Job Market

The Evolving Pharmaceutical Frontier: Navigating 2025's Landmark Shifts and Enduring Challenges

The Evolving Pharmaceutical Frontier: Navigating 2025's Landmark Shifts and Enduring Challenges

The Great Pharmaceutical Gridlock: How Patents Keep Prices Sky-High and Biosimilars at Bay

The Great Pharmaceutical Gridlock: How Patents Keep Prices Sky-High and Biosimilars at Bay

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Weight of Expectation: FDA, Obesity Drugs, and the Uneasy Dance Between Speed and Safety

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Great Weigh-In: Pharma's Fierce Battle for the Future of Obesity, and What Else Keeps Them Up at Night

The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

The Pharmaceutical Whirlwind: From Weight Loss Wonders to Mind-Altering Medicines, A New Era Unfolds

When States Take on Drug Prices: Connecticut's Bold Move and the Unfolding Legal Drama

When States Take on Drug Prices: Connecticut's Bold Move and the Unfolding Legal Drama

Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure

Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure

A Landmark Clash: India's Supreme Court Navigates Life-Saving SMA Drugs, Patents, and Public Access

A Landmark Clash: India's Supreme Court Navigates Life-Saving SMA Drugs, Patents, and Public Access

The Revolving Door: Ex-FDA Regulators Find New Homes at Pharma Giants Like Eli Lilly

The Revolving Door: Ex-FDA Regulators Find New Homes at Pharma Giants Like Eli Lilly

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs

The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines

The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines

STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers

STAT+: Sen. Sanders, others lawmakers open probe into asthma inhaler makers over pricing, patent maneuvers

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

STAT+: FDA is blasted by advocates for pursuing a deal with data provider that has ties to opioid makers

Load more